Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Thomas, Douglas D. / Turk, Boris / Wittinghofer, Alfred


IMPACT FACTOR 2018: 3.014
5-year IMPACT FACTOR: 3.162

CiteScore 2018: 3.09

SCImago Journal Rank (SJR) 2018: 1.482
Source Normalized Impact per Paper (SNIP) 2018: 0.820

Online
ISSN
1437-4315
See all formats and pricing
More options …
Volume 393, Issue 5

Issues

The kallikrein 14 gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness

Felicity Lose
  • Molecular Cancer Epidemiology Group, Genetics and Population Health Division, Queensland Institute of Medical Research, 300 Herston Road, Herston, Brisbane, QLD 4006, Australia
  • Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane, QLD 4059, Australia
  • These authors contributed equally to this study.
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Mitchell G. Lawrence
  • Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane, QLD 4059, Australia
  • These authors contributed equally to this study.
  • Present address: Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia.
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Srilakshmi Srinivasan
  • Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane, QLD 4059, Australia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Tracy O’Mara
  • Molecular Cancer Epidemiology Group, Genetics and Population Health Division, Queensland Institute of Medical Research, 300 Herston Road, Herston, Brisbane, QLD 4006, Australia
  • Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane, QLD 4059, Australia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Louise Marquart
  • Statistics Unit, Queensland Institute of Medical Research, 300 Herston Road, Herston, Brisbane, QLD 4006, Australia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Suzanne Chambers
  • Griffith Health Institute, Griffith University, Southport, Brisbane, QLD 4222, Australia
  • Viertel Centre for Cancer Research, Cancer Council Queensland, Fortitude Valley, Brisbane, QLD 4004, Australia
  • University of Queensland Centre for Clinical Research, Royal Brisbane Hospital, Herston, Brisbane, QLD 4029, Australia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Robert A. Gardiner
  • University of Queensland Centre for Clinical Research, Royal Brisbane Hospital, Herston, Brisbane, QLD 4029, Australia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Joanne F. Aitken
  • Griffith Health Institute, Griffith University, Southport, Brisbane, QLD 4222, Australia
  • Viertel Centre for Cancer Research, Cancer Council Queensland, Fortitude Valley, Brisbane, QLD 4004, Australia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Amanda B. Spurdle
  • Molecular Cancer Epidemiology Group, Genetics and Population Health Division, Queensland Institute of Medical Research, 300 Herston Road, Herston, Brisbane, QLD 4006, Australia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Jyotsna Batra
  • Molecular Cancer Epidemiology Group, Genetics and Population Health Division, Queensland Institute of Medical Research, 300 Herston Road, Herston, Brisbane, QLD 4006, Australia
  • Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane, QLD 4059, Australia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Judith A. Clements
  • Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane, QLD 4059, Australia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/

Abstract

Kallikrein 14 (KLK14) has been proposed as a useful prognostic marker in prostate cancer, with expression reported to be associated with tumour characteristics such as higher stage and Gleason score. KLK14 tumour expression has also shown the potential to predict prostate cancer patients at risk of disease recurrence after radical prostatectomy. The KLKs are a remarkably hormone-responsive family of genes, although detailed studies of androgen regulation of KLK14 in prostate cancer have not been undertaken to date. Using in vitro studies, we have demonstrated that unlike many other prostatic KLK genes that are strictly androgen responsive, KLK14 is more broadly expressed and inversely androgen regulated in prostate cancer cells. Given these results and evidence that KLK14 may play a role in prostate cancer prognosis, we also investigated whether common genetic variants in the KLK14 locus are associated with risk and/or aggressiveness of prostate cancer in approximately 1200 prostate cancer cases and 1300 male controls. Of 41 single nucleotide polymorphisms assessed, three were associated with higher Gleason score (≥7): rs17728459 and rs4802765, both located upstream of KLK14, and rs35287116, which encodes a p.Gln33Arg substitution in the KLK14 signal peptide region. Our findings provide further support for KLK14 as a marker of prognosis in prostate cancer.

Keywords: androgen regulation; Gleason score; kallikreins; KLK14; prostate cancer; single nucleotide polymorphisms (SNPs)

About the article

Corresponding author


Received: 2011-11-18

Accepted: 2012-03-13

Published in Print: 2012-05-01


Citation Information: , Volume 393, Issue 5, Pages 403–412, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/hsz-2011-0268.

Export Citation

©2012 by Walter de Gruyter Berlin Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Jatin Mehta, Shailendra Asthana, Chandi Charan Mandal, Sunita Saxena, and Natasha Kyprianou
PLOS ONE, 2015, Volume 10, Number 3, Page e0120622
[2]
Panagiota S. Filippou, Annie H. Ren, Antoninus Soosaipillai, Michail-Dimitrios Papaioannou, Dimitrios Korbakis, Roaa Safar, Eleftherios P. Diamandis, and James Conner
Clinical Biochemistry, 2018
[4]
Ana Carolina B. Stefanini, Bianca Rodrigues da Cunha, Tiago Henrique, and Eloiza H. Tajara
Disease Markers, 2015, Volume 2015, Page 1
[5]
T. Kryza, M.L. Silva, D. Loessner, N. Heuzé-Vourc'h, and J.A. Clements
Biochimie, 2016, Volume 122, Page 283
[6]
Daniela Loessner, Boris Michael Holzapfel, and Judith Ann Clements
Advanced Drug Delivery Reviews, 2014, Volume 79-80, Page 193

Comments (0)

Please log in or register to comment.
Log in